1. Home
  2. VFC vs IOVA Comparison

VFC vs IOVA Comparison

Compare VFC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo V.F. Corporation

VFC

V.F. Corporation

N/A

Current Price

$19.37

Market Cap

8.0B

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$6.90

Market Cap

6.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VFC
IOVA
Founded
1899
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
6.7B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
VFC
IOVA
Price
$19.37
$6.90
Analyst Decision
Buy
Buy
Analyst Count
24
9
Target Price
★ $20.41
$14.50
AVG Volume (30 Days)
10.0M
★ 12.8M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
★ 1.81%
N/A
EPS Growth
★ 233.33
14.84
EPS
★ 0.64
N/A
Revenue
★ $10,488,556,000.00
N/A
Revenue This Year
N/A
$58.86
Revenue Next Year
$3.03
$41.86
P/E Ratio
$31.14
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$12.46
$2.08
52 Week High
$22.27
$15.37

Technical Indicators

Market Signals
Indicator
VFC
IOVA
Relative Strength Index (RSI) 52.77 28.53
Support Level $15.83 $3.57
Resistance Level $19.71 $9.36
Average True Range (ATR) 0.82 0.56
MACD -0.23 -0.12
Stochastic Oscillator 2.74 1.30

Price Performance

Historical Comparison
VFC
IOVA

About VFC V.F. Corporation

VF designs, produces, and distributes apparel, footwear, and accessories with a focus on active and outdoor brands. Its portfolio of 10 labels includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and company-owned and partner-owned branded stores. Tracing its roots to 1899, VF has evolved into its present form through many brand acquisitions and divestitures.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: